De Novo EGFR ‐ALK and EGFR ‐ROS1 Co‐Mutations in NSCLC: Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis

De Novo EGFR ‐ALK and EGFR ‐ROS1 Co‐Mutations in NSCLC: Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis

ABSTRACT Background De novo epidermal growth factor receptor‐anaplastic lymphoma kinase (EGFR‐ALK) and EGFR‐ROS proto‐oncogene 1 (EGFR‐ROS1) co‐mutations in non‐small‐cell lung cancer (NSCLC), conditions traditionally considered mutually exclusive. We present the first large‑scale analysis of their...

Full description

Saved in:
Bibliographic Details
Main Authors: Lili Shen, Hongyu Deng, Wei Liao, Qiang Gu, Lingling Ma, Qingming Jiang, Kaihua Liu
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:Cancer Medicine
Subjects:
de novo mutation
EGFR‐ALK co‐mutation
EGFR‐ROS1 co‐mutation
non‐small cell lung cancer
targeted therapy
Online Access:https://doi.org/10.1002/cam4.71084
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items